The combined use of TKIs-ICIs (lenvatinib + pembrolizumab, cabozantinib + nivolumab +/− ipilimumab, cabozantinib + atezolizumab, camrelizumab + rivoceranib, camrelizumab + apatinib), or ICIs-ICIs (nivolumab + ipilimumab, durvalumab + tremelimumab), and ICIs-VEGF inhibitors (atezolizumab + bevacizumab, sintilimab + bevacizumab) exhibited great potential for treating advanced HCC by specifically inhibiting angiogenesis and influencing immune cell infiltration, indicating a possibility for improved therapeutic outcomes. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.